Navigation Links
Clinical trial for new tuberculosis vaccine
Date:9/11/2008

This release is available in German.

Since Monday of this week, the new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.

The scientific basis for this was laid down by the team working with Stefan H.E. Kaufmann, Director at the Max Planck Institute for Infection Biology. "The BCG tuberculosis vaccine, which was developed by French researchers, is the most frequently administered live vaccine in the world," says Kaufmann. However, BCG (short for the bacterium Bacillus Calmette-Gurind) is now frequently ineffective. The immunologist continues: "BCG has become a blunt weapon. We wanted to use genetic engineering to sharpen it so that, rather than hiding from the human immune system, it would stimulate it as much as possible."

To do this, the researchers inserted a gene into the vaccine bacteria. Leander Grode, who at the time was a member of Stefan H.E. Kaufmann's staff and is today heads a project at Vakzine Projekt Management GmbH (VPM), describes the process: "The vaccine bacteria are taken up by the scavenger cells of the human immune system and end up in their digestion chambers. The genetically engineered modification allows them to escape from the chambers and arm the immune system against the tuberculosis pathogens."

The scientific studies were initially undertaken at the Max Planck Institute for Infection Biology. In 2004, the vaccine was licensed to the Hanover-based VPN, which expedited the clinical study. Thus far, the new vaccine has proven to be extremely effective and safe in animal models. "We now need to prove that it has the same positive effect on humans, so that it qualifies for a license," explains VPM CEO Bernd Eisele. Kaufmann urges patience: "Even if the new vaccine proves to be well-tolerated, it will still have to undergo more testing to establish its efficacy. That will take at least ten years." Nevertheless - this new approach is looking hopeful.

The establishment of the Max Planck Institute for Infection Biology in 1993 was one of the first in the newly-formed German states (which previously had made up East Germany). The Institute is located on the historical Charit Mitte campus, where, 100 years ago, Robert Koch and Emil Behring made important discoveries about infectious diseases. A key reason for choosing this location was the desire to work together with the universities and clinics on clinically relevant infectious disease projects. "Interdisciplinary research into the molecular and cellular basis of infections enables the systematic development of new therapeutic and preventative measures. Basic research into infectious processes can therefore not only explain fundamental questions in biomedicine, but also make a contribution to solving significant problems in healthcare policy in the future," says Stefan H.E. Kaufmann. VPM was set up by the Federal Ministry for Education and Research and the Helmholtz Center for Infection Research as a private-public partnership. "We ensure that excellent results from basic research benefit humankind and find their way into practical applications," says Bernd Eisele.


'/>"/>

Contact: Prof. Stefan H.E. Kaufmann
kaufmann@mpiib-berlin.mpg.de
49-302-846-0500
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
2. New study spotlights National Institutes of Health grant outcomes for clinical research
3. NCI grant launches clinical trials for colon cancer screening
4. Florida researchers receive JDRF Excellence in Clinical Research Award
5. A nutritional supplement could improve the clinical situation of ICU patients
6. NIH expands national consortium dedicated to transforming clinical and translational research
7. Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
8. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
9. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
10. NHLBI issues first US von Willebrand Disease clinical practice guidelines
11. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial for new tuberculosis vaccine
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a ... device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's first ... a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... announces the commercial launch of flexible packaging for their exceptionally efficient human ... bag system extends RoosterBio’s portfolio of bioprocess media products engineered to radically ...
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
Breaking Biology Technology: